Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Barricade Therapeutics
AddedMay 6, 2026
UpdatedMay 30, 2026
Barricade Therapeutics

Barricade Therapeutics

Angel

Clinical-stage oncology company developing first-in-class oral therapies for genetically driven cancers

HQ
Fort Worth, TX, US
Founded
2017
Accelerator
Texas Medical Center Innovation logoTexas Medical Center InnovationACT 2025
Overview
Analysis
Compare
Fundraising
Employees
News

Barricade Therapeutics is a clinical-stage oncology company focused on developing first-in-class oral therapies for genetically driven cancers with significant unmet need.

The company's lead candidate BT-1501 is an investigational oral therapy targeting APC-mutant colorectal cancer, which represents approximately 80% of CRC patients. Barricade has secured over $17M in non-dilutive funding from CPRIT and additional investment from the American Cancer Society BrightEdge Fund to advance BT-1501 toward Phase 1 clinical trials.

Barricade Therapeutics - Similar Companies

Guardian Therapeutics logo

Guardian Therapeutics

Palm Therapeutics logo

Palm Therapeutics

Starton Therapeutics logo

Starton Therapeutics

MBrace Therapeutics logo

MBrace Therapeutics

mbracetrx.com

Flag Therapeutics logo

Flag Therapeutics

ApoGen Biotechnologies logo

ApoGen Biotechnologies

apogenbiotech.com

Nested Therapeutics logo

Nested Therapeutics

nestedtx.com

Bakx Therapeutics logo

Bakx Therapeutics

bakxtx.com

Launchpad Therapeutics logo

Launchpad Therapeutics

OnCusp Therapeutics logo

OnCusp Therapeutics

oncusptx.com

Treadwell Therapeutics logo

Treadwell Therapeutics

treadwelltx.com

Actuate Therapeutics logo

Actuate Therapeutics

Bridge Therapeutics logo

Bridge Therapeutics

KayoThera logo

KayoThera

kayothera.com

Bond Biosciences logo

Bond Biosciences

bond.bio

Barricade Therapeutics - Quick Facts

Who are Barricade Therapeutics' competitors?

Companies similar to Barricade Therapeutics include Guardian Therapeutics, Palm Therapeutics, Starton Therapeutics and MBrace Therapeutics.

When was Barricade Therapeutics founded?

Barricade Therapeutics was founded in 2017.

Where is Barricade Therapeutics' headquarters located?

Barricade Therapeutics' headquarters is located in Fort Worth, TX, US.

When was Barricade Therapeutics' last funding round?

Barricade Therapeutics' most recent funding round was for $293.6k (USD) in March 2026.

How much has Barricade Therapeutics raised to-date?

As of Mar 2, 2026, Barricade Therapeutics has raised a total of $17.3M (USD).

How many employees does Barricade Therapeutics have?

Barricade Therapeutics has 3 employees as of May 6, 2026.

Barricade Therapeutics - Classification

Industry
  • Biotechnology Companies
  • Pharmaceutical Companies
Ownership
  • Private
Technology
  • Pharmaceutical
Geographic Exposure
  • Americas United States
Model
  • Manufacturer
Revenue
  • Grants
  • Investment
Customer
  • Enterprises
Main Product
  • Biotech
  • Oncology Therapeutics
Tags
  • Biotechnology